Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Bladder Cancer, December 2025 Free Subscription Abstracts Retrieve all available abstracts of the following 117 articles: HTML format

Single Articles

1. MAKABE S, Hoshi K, Kaneko H, Masuishi Y, et al
   MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cells.
   Cell Death Dis. 2025;16:868.
   PubMed    
   Abstract available
   
   

2. CAI T, Feng T, Zhang W, Ge Q, et al
   Neutrophil extracellular traps-STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer.
   J Immunother Cancer. 2025;13:e012736.
   PubMed    
   Abstract available
   
   

3. MARIAPPAN P, Hart-Brooke J, Sparks R, Lord-McKenzie T, et al
   Bladder EpiCheck triggered Photodynamic Diagnosis biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy.
   Eur Urol Oncol. 2025 Nov 27:S2588-9311(25)00295.
   PubMed    
   Abstract available
   
   

4. FINOCCHIARO A, Contieri R, Piccolini A, Brin P, et al
   Assessing risk stratification in Bacillus Calmette-Guerin-treated high-grade Ta nonmuscle-invasive bladder cancer patients.
   Urol Oncol. 2025 Nov 27:S1078-1439(25)00447.
   PubMed    
   Abstract available
   
   

5. FANG CW, Shau WY, Fan SZ, Chueh JS, et al
   Comparison of spinal versus general anaesthesia in high-risk non-muscle invasive bladder cancer: study protocol for a randomised controlled trial.
   BMJ Open. 2025;15:e107824.
   PubMed    
   Abstract available
   
   

6. BROCHIER W, Nguyen S, Cesson V, Bricard O, et al
   Detection of spontaneous anti-neoepitope T-cell responses in non-metastatic bladder cancer patients.
   Front Immunol. 2025;16:1627914.
   PubMed    
   Abstract available
   
   

7. PAN X, Wen L, Li Y, Zhang Y, et al
   LLM-BCgrading: Large language model-based Chinese medical long text classification for bladder cancer grade prediction.
   Digit Health. 2025;11:20552076251393290.
   PubMed    
   Abstract available
   
   

8. MO Q, Lu Y, Wu J, Zhang X, et al
   DNA methylation of CA10 regulates the proliferation and metastasis of bladder cancer.
   J Clin Biochem Nutr. 2025;77:240-248.
   PubMed    
   Abstract available
   
   

9. ZHU K, Zhang Z, Li T, Sun Y, et al
   Integrative multi-omics and single-cell transcriptomics reveal ARHGEF12 driving chemoresistance in bladder cancer.
   Hereditas. 2025;162:234.
   PubMed    
   Abstract available
   
   

10. ALSAYEH AR, Abdelrazek EM, Oraby AH, Shokeir AA, et al
    Red single wavelength emitting up-conversion nanoparticles modulate cellular dynamics and gene expression in T24 bladder cancer cells.
    Sci Rep. 2025;15:42539.
    PubMed    
    Abstract available
    
    

11. TRAN TA, Lee HY, Choi HW
    Metabolite-mediated mechanisms linking the urinary microbiome to bladder cancer.
    J Microbiol. 2025;63:e2509001.
    PubMed    
    Abstract available
    
    

12. FRASCOLLA C, Mastroianni R, Simone G, Blandino G, et al
    The role of 3D preclinical models in the Era of precision medicine: A bladder cancer perspective.
    Gene. 2025;979:149919.
    PubMed    
    Abstract available
    
    

13. HOF JP, Kiemeney LALM, Aben KKH, van der Heijden AG, et al
    Recurrence Patterns in a Large Contemporary Cohort of Patients With Non-Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2025;24:102464.
    PubMed    
    Abstract available
    
    

14. LI C, Lv G, Yue Y, Ma G, et al
    Piperine Targets the FANCL/UBE2T Complex to Inhibit the FA Pathway and Sensitize Bladder Cancer to Cisplatin.
    Dose Response. 2025;23:15593258251404060.
    PubMed    
    Abstract available
    
    

15. YANG J, Xu Z, Tao B, Zhao Y, et al
    Causal insights into immune cell profiles, plasma metabolites, and bladder cancer: A Mendelian randomization approach.
    Medicine (Baltimore). 2025;104:e46062.
    PubMed    
    Abstract available
    
    

16. RATHORE V, Lin WW
    Decoding SIGLEC12 in Bladder Cancer: In Silico Profiling of Expression, Tumor-Immune Interactions, and Prognostic Impact.
    Medicina (Kaunas). 2025;61:1894.
    PubMed    
    Abstract available
    
    

17. GHOLAMI SS, Movassaghi M, Homayoun S, Vasdev N, et al
    Clinical Experience with URO17((R)) in the Diagnosis and Surveillance of Bladder Cancer.
    J Clin Med. 2025;14:8108.
    PubMed    
    Abstract available
    
    

18. PINTON P
    Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions.
    Cancers (Basel). 2025;17:3631.
    PubMed    
    Abstract available
    
    

19. CIUMMO V, Ciafarone A, Altamura S, Lombardi F, et al
    Exploring the Anticancer Potential of the Multistrain Probiotic Formulation OxxySlab in Bladder Cancer Cell Lines.
    Antioxidants (Basel). 2025;14:1282.
    PubMed    
    Abstract available
    
    

20. ZHANG W, Zhou K, Chen P, Du X, et al
    Phase Separation Competent TIA1 Couples Glycolytic Shutdown to CD8(+) T-Cell Activation and Shapes the Efficacy of Intravesical BCG in Bladder Cancer.
    Biology (Basel). 2025;14:1576.
    PubMed    
    Abstract available
    
    

21. HAN Y, Wang S, Xia R, Zhou B, et al
    USP54 suppresses bladder cancer proliferation, stemness, and cisplatin resistance via deubiquitination-mediated stabilization of SIRT6.
    J Chemother. 2025 Nov 26:1-13. doi: 10.1080/1120009X.2025.2591510.
    PubMed    
    Abstract available
    
    

22. TIAN H, Song J, Cong J, Zhang Z, et al
    Protein kinase D2-mediated maintenance complex component 2 phosphorylation promotes bladder cancer progression.
    J Transl Med. 2025;23:1357.
    PubMed    
    Abstract available
    
    

23. SHEN J, Li Z, Wang R, Ding G, et al
    Bladder cancer diagnostic and prognostic models from DNA methylation by multi algorithm machine learning.
    NPJ Precis Oncol. 2025 Nov 26. doi: 10.1038/s41698-025-01195.
    PubMed    
    Abstract available
    
    

24. TU S, Du W, Luo Y, Shi J, et al
    YKT6 Promotes Bladder Cancer Progression by Stabilizing beta-catenin Through USP7-Mediated Deubiquitination.
    Adv Sci (Weinh). 2025 Nov 26:e07166. doi: 10.1002/advs.202507166.
    PubMed    
    Abstract available
    
    

25. BI C, Li K, Yang Y, Shi Y, et al
    Identification of potential bladder cancer drug targets through Mendelian randomization and molecular docking.
    Discov Oncol. 2025;16:2172.
    PubMed    
    Abstract available
    
    

26. PANNHAUSEN J, Chughtai AA, Melzer MK, Ma Y, et al
    POLQ and DNA-PK inhibition in muscle-invasive bladder cancer : Enhancing radiosensitivity with novel DNA damage response inhibitors to improve radiotherapy outcomes.
    Pathologie (Heidelb). 2025 Nov 26. doi: 10.1007/s00292-025-01507.
    PubMed    
    Abstract available
    
    

27. JAIN A, Dey S, Garg D, Singh H, et al
    A multilevel ensemble model for predicting mutation types in bladder cancer.
    Per Med. 2025 Nov 26:1-10. doi: 10.1080/17410541.2025.2592530.
    PubMed    
    Abstract available
    
    

28. ZENG S, He W, Liu L, Ying Y, et al
    Chromosomal instability-guided urine sediment analysis enables non-invasive monitoring of minimal residual disease in bladder cancer.
    Int J Surg. 2025 Nov 10. doi: 10.1097/JS9.0000000000003865.
    PubMed    
    
    
    

29. KANESAKA M, Sazuka T, Kita Y, Fukuhara H, et al
    Outcomes of sequential therapy for advanced upper tract urothelial cancer and bladder cancer.
    Sci Rep. 2025;15:41872.
    PubMed    
    Abstract available
    
    

30. KOBAYASHI T, Kitamura H, Furukawa Y, Shono M, et al
    JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.
    Sci Rep. 2025;15:41773.
    PubMed    
    Abstract available
    
    

31. YUAN Q, Liu B, Yan W, Li H, et al
    FOXA2 promotes glutamine metabolism to facilitate the malignant development of bladder cancer by transcriptionally increasing GLS1 expression.
    Mutat Res. 2025;831:111920.
    PubMed    
    Abstract available
    
    

32. XIAOHUI Y, Jie L, Jiangqiao Z
    Coptisine regulates PI3K/AKT pathway to block bladder cancer progression: a study based on network pharmacology, in vitro and in vivo assays.
    Hereditas. 2025;162:232.
    PubMed    
    Abstract available
    
    

33. MUSCATELLO LV, D'Annunzio G, Franceschini T, Tugnoli C, et al
    Tumor immune microenvironment and immune phenotypes in PD-L1-tested canine urothelial carcinoma.
    BMC Vet Res. 2025;21:681.
    PubMed    
    Abstract available
    
    

34. YAMAZAWA A, Tsuchiya M, Imai S, Ikegami K, et al
    Survey of perioperative treatment in muscle-invasive bladder cancer using Japanese hospital-based claims database.
    BMC Urol. 2025 Nov 24. doi: 10.1186/s12894-025-01995.
    PubMed    
    
    
    

35. YU SY, Li HY, Wang CY, Wang WJ, et al
    Tumor-derived lactate fuels the STAT3-LCN2 pathway to promote bladder cancer malignancy and chemoresistance.
    Sci Rep. 2025;15:41610.
    PubMed    
    Abstract available
    
    

36. LI M, Li Z, Xu C, Chen Y, et al
    Semi-supervised medical image segmentation of bladder tumors based on supervised branches and uncertainty estimation.
    Sci Rep. 2025;15:41517.
    PubMed    
    Abstract available
    
    

37. SONG JJ, Zhou MT, Lee SZ, Jones JM, et al
    Safety of transurethral resection of bladder tumor in octogenarians: a NSQIP analysis.
    World J Urol. 2025;43:718.
    PubMed    
    Abstract available
    
    

38. XU B, Zhang T, He Y, Jiang A, et al
    Impact of sodium glucose cotransporter 2 inhibitors on bladder cancer and breast cancer: a pharmacovigilance analysis and Mendelian randomization study.
    Expert Opin Drug Saf. 2025 Nov 27:1-10. doi: 10.1080/14740338.2025.2595727.
    PubMed    
    Abstract available
    
    

39. DASH NR, Mohapatra V, Madhusudan KS, Pal S, et al
    Role of Portal Vein Embolization Alone in Surgical Management of Locally Advanced Gall Bladder Cancer (PROVE-GBC): A Prospective Clinical Trial.
    Indian J Surg Oncol. 2025;16:1143-1151.
    PubMed    
    Abstract available
    
    

40. GREENBERG ZF, Hutchinson TE, Kahn J, Graim KS, et al
    Urinary extracellular vesicles for high-precision bladder cancer subtyping and prognosis.
    medRxiv [Preprint]. 2025 Oct 17:2025.10.14.25338041.
    PubMed    
    Abstract available
    
    

41. XIONG S, Fan J, Huang C, He S, et al
    Single-cell and spatial transcriptomic analysis reveal cellular heterogeneity and cancer cell-intrinsic major histocompatibility complex II expression in urothelial carcinoma.
    Int J Biol Sci. 2025;21:6649-6673.
    PubMed    
    Abstract available
    
    

42. OLUMOYIN K, Rejniak K
    Modeling Adoptive Cell Therapy in Bladder Cancer from Sparse Biological Data using PINNs.
    ArXiv [Preprint]. 2025 Oct 15:arXiv:2510.13431.
    PubMed    
    Abstract available
    
    

43. FINATI M, Schiavone N, Barone B, Contieri R, et al
    Refining Active Surveillance Eligibility in Intermediate-risk Non-muscle-invasive Bladder Cancer: The Impact of Time to First Recurrence.
    Eur Urol Open Sci. 2025;82:155-159.
    PubMed    
    Abstract available
    
    

44. JIN T, Liu H, Li S, Chen H, et al
    A CT-based deep learning radiomics model for predicting HER2 expression and prognosis in non-muscle-invasive bladder cancer.
    Biomark Med. 2025 Nov 23:1-10. doi: 10.1080/17520363.2025.2590778.
    PubMed    
    Abstract available
    
    

45. YUAN F, Li X, Hong C, Huang X, et al
    Synergistic Anticancer Effects of COL6A1 Downregulation and the PD1 Inhibitor Pembrolizumab in Bladder Cancer.
    J Biochem Mol Toxicol. 2025;39:e70621.
    PubMed    
    Abstract available
    
    

46. DOIZI S, Abid N, Traxer O, Panthier F, et al
    The role of lasers in the management of bladder tumors.
    Fr J Urol. 2025;35:102970.
    PubMed    
    Abstract available
    
    

47. CAI C, Mancini J, Zhang S, Heymann J, et al
    Intravesical BCG for bladder cancer treatment complicated by disseminated BCG (BCGosis) with pericardial effusion and tamponade.
    BMJ Case Rep. 2025;18:e268921.
    PubMed    
    Abstract available
    
    

48. CHAN AW, Chiccarine A, Saxena S, Choi JW, et al
    Pan-urethral condyloma acuminatum in a bladder cancer patient.
    BMJ Case Rep. 2025;18:e269439.
    PubMed    
    Abstract available
    
    

49. ZHANG Y, Yang E, Zhang X, Shi Y, et al
    A novel sono-activatable nanoreactor induces precision intratumoral juglone generation and caspase 3/GSDME-mediated pyroptosis for treatment of bladder cancer.
    J Nanobiotechnology. 2025 Nov 22. doi: 10.1186/s12951-025-03855.
    PubMed    
    Abstract available
    
    

50. WANG T, Ma X, Wang Y, Liu H, et al
    Lactate-driven lactylation of HNRNPA1 orchestrates PKM2 splicing and glycolytic reprogramming in bladder cancer.
    J Exp Clin Cancer Res. 2025 Nov 22. doi: 10.1186/s13046-025-03591.
    PubMed    
    Abstract available
    
    

51. TANG S, Liu Y, Jin B, Zhang T, et al
    LDHA facilitates immune escape in bladder cancer through H4K5 lactylation-dependent upregulation of PD-L1.
    Biochem Pharmacol. 2025;243.
    PubMed    
    Abstract available
    
    

52. GALLUCCI FP, de Camargo JA, Viana NI, Pimenta RCA, et al
    CRISPR/Cas9-mediated MMP-9 silencing inhibits bladder cancer T24 cell invasion and migration in vitro.
    Clinics (Sao Paulo). 2025;80:100842.
    PubMed    
    Abstract available
    
    

53. OH E, Chua Y, Bahar P, Accardo ML, et al
    Pathogenic Germline Variant Prevalence and Genetic Testing Outcomes in Patients With Urothelial Carcinoma.
    Clin Genitourin Cancer. 2025;23:102451.
    PubMed    
    Abstract available
    
    

54. JAIN P, Naqvi SAA, Tripathi N, Oberoi JK, et al
    Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis.
    Clin Genitourin Cancer. 2025;23:102453.
    PubMed    
    Abstract available
    
    

55. CHE G, Zhao X, Luo R, Yu Q, et al
    Macrophage Cell and Diagnostic Biomarkers in BLCA: Integrating Machine Learning With Single-Cell Analysis.
    Clin Genitourin Cancer. 2025;23:102447.
    PubMed    
    Abstract available
    
    

56. STEIDLE M, Malshy K, Hunt TC, Cheng Z, et al
    Study Endpoint Fulfillment and FDA Approval Success in Phase III Clinical Trials of Genitourinary Malignancies.
    Clin Genitourin Cancer. 2025;23:102436.
    PubMed    
    Abstract available
    
    

57. SCHOETTLER FI, Fatehi Hassanabad M, Webb NA, Clark J, et al
    Intraoperative urothelial carcinoma tumor thrombus embolization to the heart: a case report.
    Future Cardiol. 2025;21:879-881.
    PubMed    
    Abstract available
    
    

58. DE ANGELIS M, Siech C, Jannello LMI, Di Bello F, et al
    Rates of Secondary Bladder and Rectal Cancers After External Beam Radiation for Prostate Cancer According to Age and D'amico Risk Groups in A Contemporary Cohort.
    Clin Genitourin Cancer. 2025;23:102429.
    PubMed    
    Abstract available
    
    

59. ROBESTI D, Micheli F, Rai SN, Fallara G, et al
    Addressing Uneven Treatment Discontinuation Rate in the Chemotherapy Arm of the EV-302 Phase 3 Randomized Clinical Trial: Implications for Outcome Interpretation.
    Clin Genitourin Cancer. 2025;23:102423.
    PubMed    
    Abstract available
    
    

60. ANSAB M, Rath S, Ishaque G, Araib E, et al
    Survival outcomes with enfortumab vedotin-containing regimens in metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Crit Rev Oncol Hematol. 2025;216:104945.
    PubMed    
    Abstract available
    
    

61. CHOW RD, Mamtani R
    Association Between Early on-Treatment Weight Loss With Enfortumab Vedotin Plus Pembrolizumab and Survival in Advanced Urothelial Carcinoma.
    Clin Genitourin Cancer. 2025;23:102417.
    PubMed    
    Abstract available
    
    

62. KHOSLA AA, Mendhiratta N, Jatwani K
    Urinary Diversion After Cystectomy for Bladder Cancer.
    JAMA Oncol. 2025 Dec 4. doi: 10.1001/jamaoncol.2025.3644.
    PubMed    
    
    
    

63. LIU J, Li G, Yang J, Sun B, et al
    Risk Signals of Antibody-Drug Conjugates in Bladder Cancer: A Real-World FAERS Study.
    Clin Epidemiol. 2025;17:995-1009.
    PubMed    
    Abstract available
    
    

64. ZHOU X, Bu Y, Xiao D, Li D, et al
    SMK-002 inhibits the growth of bladder cancer cells and increases their sensitivity to Osimertinib via enhancing epidermal growth factor receptor degradation.
    Korean J Physiol Pharmacol. 2025 Dec 4. doi: 10.4196.
    PubMed    
    Abstract available
    
    

65. LIUFU C, Ye S, Yin C, Zhu T, et al
    Single-cell sequencing in bladder cancer: new insights from tumor cell diversity to individualized treatment strategies.
    Cancer Cell Int. 2025 Dec 3. doi: 10.1186/s12935-025-04094.
    PubMed    
    Abstract available
    
    

66. CHEN YT, Sui J, Yang Y, Zhang H, et al
    Integration of gut microbiome and lipid metabolism reveals the anti-cancer effects of pentadecanoic acid on bladder cancer.
    BMC Med. 2025 Dec 3. doi: 10.1186/s12916-025-04554.
    PubMed    
    Abstract available
    
    

67. SHAN Y, Hou Y, Peng X, Wang N, et al
    A Rare Case of Primary Bladder Lymphoepithelial Carcinoma.
    Arch Esp Urol. 2025;78:1345-1350.
    PubMed    
    Abstract available
    
    

68. MANAV AN
    Case Report of Rare Metastasis of Renal Cell Carcinoma to the Bladder: A New Hypothesis and Literature Review.
    Arch Esp Urol. 2025;78:1329-1333.
    PubMed    
    Abstract available
    
    

69. AKAN ME, Baloglu IH, Cekmece AE, Haciosmanoglu T, et al
    Inguinoscrotal Herniation of an Orthotopic Neobladder: A Rare Case Report and Literature Review.
    Arch Esp Urol. 2025;78:1319-1322.
    PubMed    
    Abstract available
    
    

70. GUO J, Xue J, Yu Z, Dong J, et al
    Effect of Nutritional-Psychological Dual-Wheel-Driven Enhanced Recovery after Surgery Nursing on the Prognosis of Patients with Bladder Cancer: A Retrospective Cohort Study.
    Arch Esp Urol. 2025;78:1302-1311.
    PubMed    
    Abstract available
    
    

71. WANG L, Zhang F, Pan J, Shen L, et al
    Asperuloside Inhibits Bladder Cancer Cell Migration and Proliferation by Downregulating ATF6 Signalling Pathway and Inflammatory Factors.
    Arch Esp Urol. 2025;78:1277-1286.
    PubMed    
    Abstract available
    
    

72. HUANG Z, Cai Y, Zhong H, Zhou L, et al
    Effect of Continuity of Care on Cancer-Related Fatigue, Self-Care Ability and Fear of Recurrence in Patients with Intravesical Chemotherapy after Transurethral Resection of Bladder Tumors.
    Arch Esp Urol. 2025;78:1266-1276.
    PubMed    
    Abstract available
    
    

73. CHEN L, He J
    Diagnostic Values of Serum Matrix Metalloproteinase-9 and Nuclear Matrix Protein 22 for Bladder Cancer.
    Arch Esp Urol. 2025;78:1254-1260.
    PubMed    
    Abstract available
    
    

74. GUO H, Zhang L, Xu F, Liu P, et al
    Efficacy Evaluation of Multi-Slice Spiral CT in Patients with Muscle-Invasive Bladder Cancer after Neoadjuvant Chemotherapy with Gemcitabine and Cisplatin.
    Arch Esp Urol. 2025;78:1227-1235.
    PubMed    
    Abstract available
    
    

75. LI K, Niu L, Zhang X, Li T, et al
    NEAT1 is a therapeutic target for reversing T-cell exhaustion in bladder cancer.
    J Immunother Cancer. 2025;13:e013733.
    PubMed    
    Abstract available
    
    

76. HUANG Y, Gong C, Yang E, Yuan H, et al
    Natural killer cell-related gene signature predicts immune cell infiltration and improved survival in bladder cancer.
    Cytokine. 2025;197:157084.
    PubMed    
    Abstract available
    
    

77. HATTON GH, James SR, Mason AS, Gawne RT, et al
    Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation.
    Sci Adv. 2025;11:eaea6124.
    PubMed    
    Abstract available
    
    

78. KANEKO S, Nosato H, Sudo K
    Development of a Free-Viewpoint Bladder Observation System for Cystoscopy.
    Annu Int Conf IEEE Eng Med Biol Soc. 2025;2025:1-4.
    PubMed    
    Abstract available
    
    

79. ABBAS S, Soomro N, Shafik R, Heer R, et al
    Attention-enabled Explainable AI for Bladder Cancer Recurrence Prediction.
    Annu Int Conf IEEE Eng Med Biol Soc. 2025;2025:1-7.
    PubMed    
    Abstract available
    
    

80. BAK R, Fabrin K, Jensen TK, Olsen KO, et al
    Comparison of the EndoGIA versus the Endowrist stapler in intracorporeal urinary diversion in robotic assisted radical cystectomy (EGIAES) - a randomized multicentre trial.
    J Robot Surg. 2025;20:51.
    PubMed    
    Abstract available
    
    

81. MOLLER J, Seillier L, Furstberger A, Rose M, et al
    Evaluation of single-nucleotide variants in bladder cancer using prediction algorithms.
    Pathologie (Heidelb). 2025 Dec 3. doi: 10.1007/s00292-025-01518.
    PubMed    
    Abstract available
    
    

82. YANO H, Sakamoto H, Tsuruta M, Akiba D, et al
    [A Case of Bladder Squamous Cell Carcinoma Following LONG-Term-Indwelling Cystostomy].
    Hinyokika Kiyo. 2025;71:387-391.
    PubMed    
    Abstract available
    
    

83. WANG Y, Liu Z, Liu C
    Global, regional, and national burden of bladder cancer from 1990 to 2021 with projections to 2050: insights from the global burden of disease study and Mendelian randomization analysis.
    Infect Agent Cancer. 2025 Dec 2. doi: 10.1186/s13027-025-00719.
    PubMed    
    Abstract available
    
    

84. WEI J, Wei C, Chen J, Zhang X, et al
    A Clinically Practical Nomogram for Predicting Survival in Elderly Patients (>/= 65 Years) With Bladder Urothelial Carcinoma: A Study Based on SEER Database and External Validation.
    Cancer Rep (Hoboken). 2025;8:e70418.
    PubMed    
    Abstract available
    
    

85. YAN Y, Yang S, Mach KE, Chen G, et al
    Microbial Product Cocktails for Personalized Cancer Immunotherapy.
    Nat Commun. 2025;16:10625.
    PubMed    
    Abstract available
    
    

86. GUO X, Wang S, Ma Y, Du Y, et al
    Disitamab vedotin (RC48-ADC) combined with immunotherapy as neoadjuvant therapy for localized muscle-invasive bladder cancer: a multicenter real-world study.
    NPJ Precis Oncol. 2025 Dec 3. doi: 10.1038/s41698-025-01211.
    PubMed    
    Abstract available
    
    

87. FILIPPI L, Mass ACL, Arslan E, Alcin G, et al
    Is There a Role of FAPI Pet in Renal and Bladder Cancer?
    Semin Nucl Med. 2025 Dec 1:S0001-2998(25)00157.
    PubMed    
    Abstract available
    
    

88. QIANG Z, Ren C, Xie W, Yang Z, et al
    Baicalin inhibits bladder cancer progression by suppressing PD-L1-mediated M2 macrophage polarization via ALDH2.
    Biochem Biophys Res Commun. 2025;794:153036.
    PubMed    
    Abstract available
    
    

89. REMMELINK MJ, Nieuwenhuijzen JA, de Bruin DM, Oddens JR, et al
    Newly Designed Optical Coherence Tomography Catheter for Optimizing Bladder Cancer Diagnosis and Treatment: Protocol for a Feasibility Study.
    JMIR Res Protoc. 2025;14:e76644.
    PubMed    
    Abstract available
    
    

90. LIU S, Zheng J, Sun J
    Preoperative intrinsic capacity phenotypes forecast adverse physical resilience trajectories following surgery in older bladder cancer patients.
    Eur J Oncol Nurs. 2025;80:103068.
    PubMed    
    Abstract available
    
    

91. NANDI D, Kumar SK, Hasan A, Kumar V, et al
    Diagnostic accuracy of the Vesical Imaging Reporting and Data System for muscle-invasive bladder cancer and its role in reducing repeat transurethral resection of bladder tumor: A systematic review.
    Bladder (San Franc). 2025;12:e21200065.
    PubMed    
    Abstract available
    
    

92. QIN C, Peng Y, Wang F, Song Y, et al
    Clinical significance of tumor location in non-muscle-invasive bladder cancer: A single-center longitudinal cohort analysis.
    Bladder (San Franc). 2025;12:e21200057.
    PubMed    
    Abstract available
    
    

93. HUYNH TNA, Wei X, Arulshankar S, Lam D, et al
    (18)F-fluorodeoxyglucose positron emission tomography combined with computed tomography for bladder cancer staging: Diagnostic accuracy and prognostic implications.
    Bladder (San Franc). 2025;12:e21200066.
    PubMed    
    Abstract available
    
    

94. LV Z, Feng Y, Guo B, Jiang B, et al
    Real-world management of T1 high-grade bladder cancer: A 14-year retrospective single-center study.
    Bladder (San Franc). 2025;12:e21200060.
    PubMed    
    Abstract available
    
    

95. CAI L, Bai R, Cao Q, Sun W, et al
    A non-invasive MRI-based multimodal fusion deep learning model (MF-DLM) for predicting overall survival in bladder cancer: a multicentre retrospective study.
    EClinicalMedicine. 2025;90:103640.
    PubMed    
    Abstract available
    
    

96. CHU J, Zhai J, Ma Q, Zhang Z, et al
    A case-based review of urachal carcinoma with mixed small cell neuroendocrine and adenocarcinoma components, with one new case report and analysis of nine published cases.
    Front Endocrinol (Lausanne). 2025;16:1676835.
    PubMed    
    Abstract available
    
    

97. DONG H, Li H, Chen S, Wang Q, et al
    Comprehensive Bioinformatics Analysis and Validation of the Mechanism of Glutamic-pyruvic Transaminase 2 in Bladder Cancer.
    J Cancer. 2025;16:4357-4370.
    PubMed    
    Abstract available
    
    

98. SHI Z, Zhang H, Yang C
    Re: Kaushik P. Kolanukuduru, Reuben Ben-David, Sarah Lidagoster, et al. Comparative Effectiveness of Bacillus Calmette-Guerin and Sequential Intravesical Gemcitabine and Docetaxel for Treatment-naive Intermediate-risk Non-muscle-invasive Bladder Cance
    Eur Urol Open Sci. 2025;82:168-169.
    PubMed    
    
    
    

99. JOHN KA, Odibo AO, Soliman AM, Abayomi M, et al
    The Future of Bladder Cancer Therapies: Integrating Hydrogel Scaffolds for Epigenetic Regulator Delivery.
    Cureus. 2025;17:e95675.
    PubMed    
    Abstract available
    
    

100. ZHENG B, Zhang F, Wang H, Zuo W, et al
     SLC7A11-independent disulfidptosis induced by a two-pronged delivery strategy for bladder cancer chemotherapy and cisplatin-resistance reverse.
     Mater Today Bio. 2025;35:102547.
     PubMed    
     Abstract available
     
     

101. BUCHLER T, Pehalova Kusova L, Pirshtuk A, Muzik J, et al
     Second Primary Cancer After Bladder Cancer: A Comprehensive Analysis of a National Cancer Registry.
     Cancer Med. 2025;14:e71427.
     PubMed    
     Abstract available
     
     

102. ZHANG Y, Ye S, Wang S, Ding Q, et al
     SCD1 drives bladder cancer progression and trametinib sensitivity.
     Pathol Res Pract. 2025;277:156287.
     PubMed    
     Abstract available
     
     

103. FENG W, Wang Y, Wu K, Zeng J, et al
     Global, regional, and national bladder cancer burden from 1990 to 2021 and forecasts to 2050: a systematic analysis of the global disease burden study in 2021.
     BMC Public Health. 2025 Nov 29. doi: 10.1186/s12889-025-25611.
     PubMed    
     Abstract available
     
     

104. LURAGHI P, Perrone V, Castelletti D, Losi S, et al
     Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases.
     Adv Ther. 2025 Nov 29. doi: 10.1007/s12325-025-03420.
     PubMed    
     Abstract available
     
     

105. HATAYAMA T, Takemoto K, Kobatake K, Miura K, et al
     Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial-Mesenchymal Transition Pathway.
     Cancer Sci. 2025 Nov 29. doi: 10.1111/cas.70284.
     PubMed    
     Abstract available
     
     

106. TAN Z
     Comments on "Unleashing the therapeutic potential of tumor-draining lymph nodes: spotlight on bladder cancer".
     J Transl Med. 2025;23:1362.
     PubMed    
     
     
     

107. WEI YY, Zhao Y, Sun SW, Liu J, et al
     [Advances in the application of patient-derived organoid models in urothelial cancer research].
     Zhonghua Wai Ke Za Zhi. 2025;63:1171-1176.
     PubMed    
     Abstract available
     
     

108. LEE DY, Kim MH, Ha E, Shin S, et al
     Changes in proteinuria and the risk of urogenital cancer in Korean men.
     Maturitas. 2025;203:108754.
     PubMed    
     Abstract available
     
     

109. YAMAMOTO S, Higa K, Kurokawa K, Bamba H, et al
     Cisplatin-induced AKI risk stratification and safety of dose reduction in urothelial carcinoma patients with renal impairment.
     Actas Urol Esp (Engl Ed). 2025;49:501864.
     PubMed    
     Abstract available
     
     

110. MISZCZYK M, Bilski M, Koi T, Konat-Baska K, et al
     Metastasis-directed Therapy in the Management of Urothelial Carcinoma: A Systematic Review and Meta-analysis.
     Eur Urol Focus. 2025;11:638-647.
     PubMed    
     Abstract available
     
     

111. KOBARI Y, Iizuka J, Kondo H, Ichioka M, et al
     Renal Function With Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study in Japan.
     Anticancer Res. 2025;45:5645-5654.
     PubMed    
     Abstract available
     
     

112. 
     Correction to "Outcomes of BCG vs upfront radical cystectomy for high-risk non-muscle-invasive bladder cancer".
     BJU Int. 2025 Nov 24. doi: 10.1111/bju.70090.
     PubMed    
     
     
     

113. GONZALEZ-PADILLA DA, Subiela JD, Villacampa-Auba F
     Immune checkpoint inhibitors for high-risk non-muscle invasive bladder cancer: Lessons learnt from the CREST and POTOMAC trials.
     J Urol. 2025 Nov 25:101097JU0000000000004864. doi: 10.1097/JU.0000000000004864.
     PubMed    
     
     
     

114. AYDIN O, Cinar I, Ozdemir B
     Recurrent Mullerianosis in the Bladder: A Rare Case Report That May Mimic an Adenocarcinoma.
     Urol Int. 2025;109:653-656.
     PubMed    
     Abstract available
     
     

115. ZHAO Y, Li P, Shen Z, Yao S, et al
     Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence.
     BMC Cancer. 2025;25:1796.
     PubMed    
     Abstract available
     
     

116. LAN K, Zhang Y, Luo Y, Hong T, et al
     Global, regional, and national burdens of bladder cancer attributable to high fasting plasma glucose from 1990 to 2021, with future forecasts to 2050: a systematic analysis for the global burden of disease study 2021.
     BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15359.
     PubMed    
     Abstract available
     
     

117. DU C, Wei W, Hu M, He J, et al
     Enhancing prediction accuracy for muscle invasion in bladder cancer using a dual-energy CT-based interpretable model incorporating habitat radiomics and deep learning.
     BMC Cancer. 2025;25:1842.
     PubMed    
     Abstract available